首頁 > 市場調查報告書 > 製藥

自體免疫疾病

類風濕性關節炎藥物市場規模、佔有率和成長分析（按分子、銷售管道、給藥途徑和地區分類）：產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898017

類風濕性關節炎藥物市場規模、佔有率和成長分析（按分子、銷售管道、給藥途徑和地區分類）：產業預測（2026-2033 年）

Rheumatoid Arthritis Drugs Market Size, Share, and Growth Analysis, By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, Over-the-Counter (OTC)), By Route of Administration, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球類風濕性關節炎藥物市場規模將達到 273.5 億美元，到 2025 年將達到 289.9 億美元，到 2033 年將達到 462.1 億美元，預測期（2026-2033 年）的複合年成長率為 6%。

由於類風濕性關節炎發病率上升及其關節併發症數量不斷增加，全球類風濕性關節炎治療市場正經歷顯著成長。推動市場擴張的因素有很多，包括類風濕性關節炎盛行率的上升、對有效療法的需求不斷成長以及專利到期後生物相似藥的興起。此外，人口老化也增加了對傳統DMARDs（緩解疾病抗風濕藥）的依賴。政府旨在提高公眾對類風濕性關節炎症狀的認知並探索創新治療方法的措施也進一步推動了市場發展。與主要產業參與者的合作促進了研發，而生物製藥與DMARDs聯合治療的日益普及，則滿足了需要個人化治療方案的患者的治療需求。

全球類風濕性關節炎藥物市場成長要素

全球類風濕性關節炎的不斷上升是推動全球類風濕性關節炎藥物市場擴張的主要因素。人口老化以及生活方式和飲食習慣的變化，都加劇了疾病的發生率。這一趨勢增加了對有效治療類風濕性關節炎藥物的需求，進一步推動了市場成長。隨著人們對該疾病的認知不斷提高，對創新治療方法的需求也日益迫切，類風濕性關節炎藥物市場持續發展，為治療方案的改進和患者照護的提升提供了巨大的機會。

限制全球類風濕性關節炎藥物市場的因素

長期使用某些類風濕性關節炎藥物（尤其是生物製藥和JAK抑制劑）的安全性問題，是限制市場成長的一大因素。潛在的不良反應，包括感染疾病風險、心血管問題和惡性腫瘤，往往會使患者和醫療服務提供者在採用這些治療方法時持謹慎態度。因此，對副作用的擔憂阻礙了這些治療方法的推廣和應用，最終減緩了其普及速度並限制了市場滲透率。這種猶豫不決影響了患者的整體治療選擇，並阻礙了類風濕性關節炎藥物領域的發展。

全球類風濕性關節炎治療市場趨勢

全球類風濕性關節炎治療市場的一個顯著趨勢是生物製藥（包括單株抗體和JAK抑制劑）的應用日益廣泛。這些先進療法具有標靶作用機制，能夠提高療效並最大限度地減少副作用，尤其適用於中重度患者。隨著醫療服務提供者和患者對這些創新療法的益處認知不斷提高，其應用率也顯著上升。這項變化反映了整個產業向精準醫療的轉變，使生物製藥成為有效治療類風濕性關節炎的首選方案。

艾伯維公司（美國）
輝瑞公司（美國）
安進公司（美國）
禮來公司（美國）
百時美施貴寶公司（美國）
強生公司（美國）
諾華公司（瑞士）
F. Hoffmann-La Roche Ltd（瑞士）
UCB SA（比利時）
武田藥品工業株式會社（日本）
安斯泰來製藥株式會社（日本）
衛材株式會社（日本）
中外製藥株式會社（日本）
協和麒麟株式會社（日本）
太陽製藥工業有限公司（印度）
魯賓有限公司（印度）
Zydus Lifesciences Limited（印度）
印度西普拉有限公司
瑞迪博士實驗室有限公司（印度）

結論與建議

簡介目錄

Product Code: SQSG35I2003

Global Rheumatoid Arthritis Drugs Market size was valued at USD 27.35 Billion in 2024 and is poised to grow from USD 28.99 Billion in 2025 to USD 46.21 Billion by 2033, growing at a CAGR of 6% during the forecast period (2026-2033).

The global rheumatoid arthritis drugs market is experiencing significant growth driven by rising arthritis incidences and joint complications. Several factors are contributing to this market expansion, including an increase in the prevalence of rheumatoid arthritis, heightened demand for effective treatments, and the release of patents leading to the rise of biosimilars. Additionally, a growing geriatric population is fostering an increased reliance on conventional DMARDs. Government initiatives aimed at enhancing awareness of rheumatoid arthritis symptoms and exploring innovative treatment options further boost the market. Collaborative efforts with key industry players facilitate research and development, while the popularity of combination therapies combining biologics and DMARDs is on the rise, catering to the therapeutic needs of patients requiring personalized treatment approaches.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rheumatoid Arthritis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rheumatoid Arthritis Drugs Market Segments Analysis

Global Rheumatoid Arthritis Drugs Market is segmented by Molecule, Sales Channel, Route of Administration and region. Based on Molecule, the market is segmented into Pharmaceuticals andBiopharmaceuticals. Based on Sales Channel, the market is segmented into Prescription and Over-the-Counter (OTC). Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rheumatoid Arthritis Drugs Market

The growing prevalence of rheumatoid arthritis worldwide is a key factor driving the expansion of the global rheumatoid arthritis drugs market. An aging population, coupled with lifestyle factors and dietary habits, has contributed to the increasing incidence of this condition. This trend has resulted in a heightened demand for effective treatments that can manage rheumatoid arthritis, further propelling market growth. As awareness of the disease increases and the need for innovative therapies becomes more pressing, the market for rheumatoid arthritis medications continues to evolve, indicating a significant opportunity for advancements in treatment options and patient care.

Restraints in the Global Rheumatoid Arthritis Drugs Market

Concerns regarding the safety of long-term usage of specific rheumatoid arthritis medications, particularly biologics and JAK inhibitors, significantly hinder the growth of the market. Both patients and healthcare providers often exercise caution in adopting these therapies due to potential adverse effects, including the risk of infections, cardiovascular issues, and malignancies. As a result, the apprehension surrounding the side effects stifles the willingness to embrace and integrate these treatments, ultimately slowing their adoption and limiting their market penetration. This hesitation impacts overall treatment options for patients and stalls progression within the rheumatoid arthritis drugs sector.

Market Trends of the Global Rheumatoid Arthritis Drugs Market

The global rheumatoid arthritis drugs market is witnessing a pronounced trend towards the growing adoption of biologic therapies, including monoclonal antibodies and JAK inhibitors. These advanced treatments offer targeted mechanisms of action that result in enhanced efficacy and minimized side effects, catering particularly to patients with moderate to severe forms of the disease. As healthcare providers and patients increasingly recognize the benefits of these innovative solutions, there has been a notable rise in their uptake. This shift reflects a broader movement within the industry towards precision medicine, positioning biologics as a preferred choice for effective rheumatoid arthritis management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Analysis

Global Rheumatoid Arthritis Drugs Market Size by Molecule & CAGR (2026-2033)

Market Overview
Pharmaceuticals
- NSAIDs
- Analgesics
- DMARDs
- Glucocorticoids
Biopharmaceuticals
- Biologics
- TNF-a antagonists
- T-cell inhibitors
- CD20 antigen
- JAK inhibitors
- anti-IL6 biologics
- Biosimilars
- CD20 antigen
- TNF-a antagonists

Global Rheumatoid Arthritis Drugs Market Size by Sales Channel & CAGR (2026-2033)

Market Overview
Prescription
Over-the-Counter (OTC)

Global Rheumatoid Arthritis Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Parenteral

Global Rheumatoid Arthritis Drugs Market Size & CAGR (2026-2033)

North America (Molecule, Sales Channel, Route of Administration)
- US
- Canada
Europe (Molecule, Sales Channel, Route of Administration)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Molecule, Sales Channel, Route of Administration)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Molecule, Sales Channel, Route of Administration)
- Brazil
- Rest of Latin America
Middle East & Africa (Molecule, Sales Channel, Route of Administration)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chugai Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Lifesciences Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments